Peripheral Helper T-cells in Common Variable ImmunoDeficiency (NCT07255157) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Peripheral Helper T-cells in Common Variable ImmunoDeficiency
France60 participantsStarted 2025-12
Plain-language summary
The aim is to determine whether whether Tph could support non-infectious complications through providing help to pathological B-cells.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Male or female;
* Age ≥ 18 years;
* Standard criteria will be applied to diagnose CVID, specifically requiring: 1) low serum IgG level \<5 g/L, combined with low IgM- and/or IgA-isotype concentrations \<0.4 g/L or \<0.7 g/L, respectively; 2) poor antibody responses to immunization or infection; and 3) exclusion of other defined forms of secondary hypogammaglobulinemias. Patients meeting the definitional criteria for CVID will be included, regardless of the duration of the disease or the treatment received (gammaglobulins substitution or not);
* Being affiliated to health insurance;
* Willing to participate and to sign informed consent.
Exclusion Criteria:
* Patients on corticosteroids and/or immunosuppressants;
* Patients with a primary immunodeficiency genetically characterized, such as Bruton disease our HyperIgM syndrome;
* Patients with an active chronic infection;
* Pregnant or breastfeeding women;
* Persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.
What they're measuring
1
Ability of Tph to promote differentiation and antibody production by memory B cells (B-T co-culture)